Skip to main content

Advertisement

Table 1 Characteristics of patients who were diagnosed with de novo stage IV breast cancer

From: Could local surgery improve survival in de novo stage IV breast cancer?

Variable No. Patients(N = 313) Percentage
Age at diagnosis
  ≤ 50 189 39.6
  > 50 124 60.4
Menopause status
 Menses 193 61.7
 Menopause 115 36.7
 Unknown 5 1.6
Biopsy
 Mass resection 27 8.6
 Core needle 229 73.2
 Fine needle 1 0.3
 Unknown 56 17.9
Tumor size
  ≤ 5 cm 174 55.6
  > 5 cm 120 38.3
 Unknown 19 6.1
Lymph node involvement
 N0 28 8.9
 N1 44 14.1
 N2 71 22.7
 N3 129 41.2
 Unknown 41 13.1
Hormone receptor status
 + 212 67.7
 - 94 30.0
 Unknown 7 2.2
HER2 receptor status
 Amplified 132 42.2
 No-amplified 161 51.4
 Not known or equivocal(2+) 20 6.4
Molecular subtype
 Luminal A 55 17.6
 Luminal B 141 45.0
 HER2 56 17.9
 Triple negative 33 10.5
 Unknown* 28 8.9
Surgery
 Yes 188 60.1
 No 125 39.9
Type of surgery
 Modified radical mastectomy 181 96.3
 Lumpectomy 3 1
 Simple mastectomy 4 1.3
Margin status
 Negative 184 97.9
 Positive 4 2.1
Endocrine therapy$
 Yes 123 39.3
 No 190 60.7
Anti-HER2 therapy$
 Yes 71 22.7
 No 239 76.4
 Unknown 3 1
Chemotherapy(first line regimen)$
 CAF/CEF 9 2.9
 Taxane based/taxane +anthracyline 241 77.0
 Platinum based 17 5.4
 Others 20 6.4
 Unknown 26 8.3
Bisphosphonate
 Yes 92 29.4
 No 221 70.6
OFS*
 Yes 58 18.5
 No 255 81.5
Radiotherapy
 Yes 99 31.6
 No 184 58.8
 Unknown 30 9.6
Viscera metastasis
 Yes 167 53.4
 No 146 46.6
Bone metastasis
 Yes 171 54.6
 No 142 45.4
CNS metastasis*
 Yes 11 3.5
 No 302 96.5
Soft tissue metastasis
 Yes 139 44.4
 No 174 55.6
No. of metastasis sites
  ≤ 3 288 92.0
  > 3 25 8.0
Overall survival(months)
 Median 62
 95% Confidence interval 45.79–78.21
  1. Abbreviation: *OFS = ovarian function suppression; CNS = central nervous system; $Endocrine therapy were subsequent to chemotherapy, anti-HER2 therapy were incorporated into or subsequent to chemotherapy